Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide versus placebo for central and peripheral inflammation in Alzheimer's disease
2022-003384-24Phase 3Active
- Sponsor
- Novo Nordisk
- Start
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Semaglutide with Placebo (2 arms). Primary endpoint: Co-primary endpoints. Started Jan 2023; status: active.
02
Drugs
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2022-003384-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003384-24.